类风湿关节炎糖皮质激素处方的变异性及医生偏好对长期使用的影响
基于2006-2015年Medicare数据,研究评估风湿科医生糖皮质激素处方偏好差异及其对RA患者长期使用的影响。偏好强烈预测6-9个月后泼尼松≥5 mg/天的使用(最高与最低五分位预测概率22% vs 11%)。
要点
- 医生偏好是RA患者长期使用糖皮质激素的最强预测因素之一。
- 最高与最低五分位医生的患者6-9个月后泼尼松≥5 mg/天预测概率为22% vs 11%。
核心结论
- 类风湿关节炎糖皮质激素处方在风湿科医生间变异很大,医生偏好是患者长期使用糖皮质激素的最强预测因素之一。
研究设计与样本
- 利用2006-2015年Medicare数据建立两个队列:队列1为接受DMARDs的RA患者,计算医生糖皮质激素处方偏好;队列2为接受稳定DMARD治疗的RA患者,评估偏好对6-9个月后泼尼松≥5 mg/天使用的预测。
主要发现
- 队列1共1,272,644年度观察、385,597例患者,计算6,875名风湿科医生的偏好(28,936年度观察)。
- 队列2共155,539例稳定DMARD治疗患者,偏好与6-9个月后泼尼松≥5 mg/天使用强烈相关。
- 最高与最低五分位偏好医生患者预测使用概率分别为22%(95%CI 21.7-22.7)和11%(95%CI 10.2-10.9)。
临床怎么用
- 提示应关注风湿科医生糖皮质激素处方偏好差异,以限制长期使用至最低必要剂量。
- 需更强证据指导RA治疗,以减少长期糖皮质激素使用的不必要变异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Glucocorticoids are recommended for short-term use in rheumatoid arthritis (RA), but many patients continue receiving long-term therapy. We evaluated the variability in glucocorticoid prescribing across rheumatologists to inform interventions to limit long-term glucocorticoid use to the lowest dose necessary. METHODS: Two cohorts were created using Medicare data from 2006 to 2015. Using cohort 1 (RA patients receiving disease-modifying antirheumatic drugs [DMARDs]), we calculated each rheumatologist's "provider preference" for glucocorticoids (frequency of use compared to other providers), using the ratio of observed to expected number of patients receiving glucocorticoids to account for case mix. In cohort 2 (RA patients receiving stable DMARD therapy), we evaluated whether provider preference for glucocorticoids could independently predict use of ≥5 mg/day of glucocorticoids 6-9 months after initiation of DMARD therapy. RESULTS: Using cohort 1 (1,272,644 yearly observations; 385,597 patients), we calculated provider preference among 6,875 rheumatologists (28,936 yearly observations). Provider preference was highly variable, with physicians at the lowest and upper quartiles prescribing glucocorticoids 33% less often to 31% more often (25th and 75th percentiles, respectively) than expected. In cohort 2 (155,539 patients receiving stable DMARD therapy), provider preference was strongly associated with glucocorticoid use ≥5 mg/day at 6-9 months, with a predicted probability of use of 22% (95% confidence interval [95% CI] 21.7-22.7) versus 11% (95% CI 10.2-10.9) for a patient seeing a provider in the highest versus lowest quintile of preference. CONCLUSION: Glucocorticoid prescribing for RA varies greatly among rheumatologists, and provider preference is one of the strongest predictors of a patient's long-term glucocorticoid use. These findings raise quality of care concerns and highlight the need for stronger evidence to guide RA treatment.
引用
- George MD, Baker JF, Wallace B, et al. Variability in Glucocorticoid Prescribing for Rheumatoid Arthritis and the Influence of Provider Preference on Long-Term Use of Glucocorticoids. Arthritis Care Res (Hoboken). 2021. PMID: 32702188. doi:10.1002/acr.24382
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。